secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001213900-24-030623
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara raises ~$45M in private placement; reports positive TARA-002 data and FDA alignment for IV Choline Chloride
--------------------------------------------------------------------------------

- Private placement: gross proceeds ~$45M from 9.14M shares and 1.7M pre-funded warrants at $4.15; common warrants exercisable at $5.25.
- FDA alignment on registrational path for IV Choline Chloride in PN patients; Phase 2b/3 THRIVE-3 to start in 1H 2025.
- TARA-002 three-month CR 38% (6/16) in NMIBC; 63% in CIS-only; 43% in BCG-Unresponsive/Experienced; no Grade 3+ treatment-related AEs.
- ADVANCED-2 Phase 2 trial adds 80 KE dose cohort and systemic priming; six-month data expected 2H 2024; plans TARA-002 + pembrolizumab combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/ea0203128-8k_protar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-030623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer